Impact of belantamab mafodotin vs pomalidomide/low-dose dexamethasone treatment on health-related quality of life and vision-related functioning in patients with relapsed/refractory multiple myeloma

被引：0
|
作者：
Dimopoulos, Meletios [1 ]
Weisel, Katja [2 ]
Hungria, Vania [3 ]
Sapra, Sandhya [4 ]
Sule, Neal [4 ]
Li, Mary [4 ]
McKeown, Astrid [5 ]
Kazeem, Gbenga [5 ]
Polinkovsky, Margaret [6 ]
Meunier, Juliette [7 ]
Loubert, Angely [7 ]
Bunod, Laurine [7 ]
Perera, Sue [8 ]
Currie, Brooke [9 ]
机构：
[1] Natl & Kapodistrian Univ Athens, Athens, Greece
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Clin Sao Germano, Dept Hematol, Sao Paulo, Brazil
[4] GSK, Upper Providence, PA USA
[5] GSK, Stevenage, Herts, England
[6] GSK, Durham, NC USA
[7] Modus Outcomes, Lyon, France
[8] GSK, London, England
[9] GSK, Rockville, MD USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-252
引用
收藏
页码：S174 / S175
页数：2
相关论文
共 50 条
  • [21] A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE
    Palumbo, A.
    Dimopoulos, M. A.
    Richardson, P. G.
    Siegel, D. S.
    Cavo, M.
    Corradini, P.
    Weisel, K. C.
    Delforge, M.
    Chen, C.
    Goldschmidt, H.
    Jagannath, S.
    Lockhorst, H. M.
    Moreau, P.
    Plesner, T.
    Sternas, L.
    Peluso, T.
    Hong, K.
    Herring, J.
    Yu, X.
    Zaki, M. H.
    San Miguel, J.
    HAEMATOLOGICA, 2016, 101 : 535 - 536
  • [22] Impact of baseline ocular conditions on belantamab mafodotin-related corneal events in relapsed/refractory multiple myeloma
    Popat, Rakesh
    Kazantzi, Aikaterini
    Kleinman, David
    Lichenstein, Carolyn
    Paka, Prani
    Salter, John
    Byrne, Julie
    Doherty, Allison
    Esposti, Simona Degli
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 65 - 66
  • [23] OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS
    De Miguel, D.
    Gil, A.
    Golbano, N.
    Diaz, M.
    Guillen, H.
    Vazquez, A.
    Pinedo, B.
    HAEMATOLOGICA, 2017, 102 : 790 - 791
  • [24] Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
    Plesner, Torben
    Dimopoulos, Meletios A.
    Oriol, Albert
    San-Miguel, Jesus
    Bahlis, Nizar J.
    Rabin, Neil
    Suzuki, Kenshi
    Yoon, Sung-Soo
    Ben-Yehuda, Dina
    Cook, Gordon
    Goldschmidt, Hartmut
    Grosicki, Sebastian
    Qin, Xiang
    Fastenau, John
    Garvin, Wendy
    Carson, Robin
    Renaud, Thomas
    Gries, Katharine S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (01) : 132 - 139
  • [25] Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
    Delforge, Michel
    Shah, Nina
    Miguel, Jesus San F.
    Braverman, Julia
    Dhanda, Devender S.
    Shi, Ling
    Guo, Shien
    Yu, Peiwen
    Liao, Weiqin
    Campbell, Timothy B.
    Munshi, Nikhil C.
    BLOOD ADVANCES, 2022, 6 (04) : 1309 - 1318
  • [26] Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab
    Pierceall, William E.
    Bahlis, Nizar
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy J.
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Srinivas, Shanti
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald P.
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Chung, Weiyuan
    Serbina, Natalya
    Zafar, Faiza
    Agarwal, Amit
    Thakurta, Anjan
    BLOOD, 2018, 132
  • [27] Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study
    Hungria, Vania
    Weisel, Katja
    Currie, Brooke
    Perera, Sue
    Sule, Neal
    He, Wei
    Davy, Katherine
    McKeown, Astrid
    Sapra, Sandhya
    Nelsen, Linda
    Li, Mary
    Barale, Sophie
    Boyle, Julia
    McPoyle, Kaytlyn
    Dimopoulos, Meletios Athanasios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S505 - S505
  • [28] Health-Related Quality of Life in Lenalidomide and Bortezomib Treated Patients with Relapsed/Refractory Multiple Myeloma
    Kyriakou, Charalampia
    Murphy, Philip
    Petrucci, Maria Teresa
    Bacon, Pamela
    Lewis, Philip
    Gilet, Helene
    Arnould, Benoit
    Vande Broek, Isabelle
    Leleu, Xavier
    BLOOD, 2015, 126 (23)
  • [29] DREAMM-2: Belantamab mafodotin (belamaf; GSK2857916) effect on disease symptoms and health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM)
    Weisel, K.
    Popat, R.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Voorhees, P.
    Cohen, A.
    Opalinska, J.
    Gutierrez, B.
    Gorsh, B.
    He, Z.
    Eliason, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 103 - 104
  • [30] Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide
    Beksac, Meral
    Garcia, Esther Gonzalez
    Delimpasi, Sosana
    Robak, Pawel
    Karunanithi, Kamaraj
    De Arriba, Felipe
    Radocha, Jakub
    Kim, Kihyun
    Voloshin, Sergey
    Zherebtsova, Vera
    Osipov, Iurii
    Mateos, Maria-Victoria
    Zafar, Syed F.
    Pour, Ludek
    Spicka, Ivan
    Suzuki, Kazuhito
    Du, Xin
    Wilkes, Jodie
    Maroj, Brijesh
    Morris, Kristin
    Ma, Jie
    Polinkovsky, Margaret
    Wang, Zhaohui
    Zhou, Xiaoou L.
    Fulci, Giulia
    Sule, Neal
    Kremer, Brandon
    Opalinska, Joanna
    Trudel, Suzanne
    Dimopoulos, Meletios A.
    BLOOD, 2024, 144 : 4731 - 4733
12345